Establishment of novel molecular targeted therapy focused on apoptosis induction in ovarian clear cell adenocarcinoma
| Project/Area Number |
15H06173
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-08-28 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | PI3K/mTOR阻害薬 / 卵巣明細胞癌 / アポトーシス / 婦人科悪性腫瘍 / 卵巣癌 / PI3K/mTOR阻害剤 / 分子標的薬 / 癌 / 分子標的治療 / 卵巣明細胞腺癌 / 婦人科腫瘍 |
|---|
| Outline of Final Research Achievements |
We confirmed that a PI3K / mTOR inhibitor suppressed the growth signal and showed the antitumor effect in a concentration-dependent manner in ovarian clear cell adenocarcinoma cell line. In addition, the the PI3K/mTOR inhibitor leaded apoptosis in ovarian clear cell adenocarcinoma cell lines with wild type TP53 more effectively than that with TP53 mutation. The absence of TP53 mutation may be a promising biomarker for using PI3K / mTOR inhibitors for patients with ovarian clear cell adenocarcinoma. We are investigating whether combination with PI3K/mTOR inhibitor and other molecular target drugs or anticancer drugs can induce more efficient apoptosis, and MDM 2 inhibitors and MEK inhibitors are considered to be promising candidates.
|
Report
(3 results)
Research Products
(4 results)
-
[Journal Article] Synergistic antitumor effects of combination of PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging.2016
Author(s)
Inaba K, Oda K, Aoki K, Sone K, Ikeda Y, Miyasaka A, Kashiyama T, Fukuda T, Makii C, Arimoto T, Wada-Hiraike O, Kawana K, Yano T, Osuga Y, Fujii T
-
Journal Title
Oncotarget
Volume: 7
Issue: 20
Pages: 29577-29591
DOI
NAID
Related Report
Peer Reviewed / Open Access
-
-
[Journal Article] MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53.2016
Author(s)
Makii C, Oda K, Ikeda Y, Sone K, Hasegawa K, Uehara Y, Nishijima A, Asada K, Koso T, Fukuda T, Inaba K, Oki S, Machino H, Kojima M, Kashiyama T, Mori-Uchino M, Arimoto T, Wada-Hiraike O, Yano KK, Fujiwara K, Aburatani H, Osuga Y, Fujii T.
-
Journal Title
Oncotarget
Volume: 7
Issue: 46
Pages: 75328-75338
DOI
Related Report
Peer Reviewed / Open Access
-
